Genetic mutations in HRAS, KRAS genes linked to childhood cancers
Hereditary changes in genes are often the cause of rare diseases. For example, disease-causing gene variants (PVs) in the ...
C&EN3d
Degrader takes out many forms of KRas
Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...
healthcare-in-europe.com3d
KRAS “degrader” could lead to treatment for millions of cancer patients
New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...
Small-molecule drug shows potential for hard to treat cancers
Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...
Combination treatment improves response to immunotherapy for lung cancer, mouse study shows
Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of ...
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains 29 different patent families ...
加科思-B(01167)自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请在中国获批
加科思-B(01167)公布，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请(IND)已经获得国家药品监督管理局(NMPA) 药品审评中心(CDE)批准。此前，美国的IND申请也已经获得美国食品药品监督管理局(FDA)批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。 KRAS广泛存在于多种肿瘤突变，约23%-25%的癌症患者带有KRAS突变，全球每年新增约270 ...
ORR 62.8%，KRAS G12C 抑制剂格来雷塞拟纳入突破性疗法
9 月 26 日，CDE 官网显示，加科思 KRAS G12C 抑制剂「格来雷塞」一项在研适应症拟纳入突破性疗法，联合西妥昔单抗拟用于经 2 线标准治疗（包括奥沙利铂、伊立替康、5-氟尿嘧啶，联合或不联合抗VEGF单抗）失败、KRAS G12C 突变阳性的手术无法切除的局部晚期或转移性结直肠癌患者。图片来源：CDE ...
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...
【掌上药店】KRAS G12C突变靶向药物的进展与展望
KRAS基因在人类肿瘤中扮演着重要角色，是最常见的致癌基因之一。过去，针对KRAS的直接治疗手段非常有限，预后不佳。然而，随着KRAS G12C亚突变的发现，这一领域迎来了突破。KRAS ...
FDA破冰！加科思-B(01167) Pan-KRAS抑制剂JAB-23E73临床实验获批，抗癌领域迎来变革曙光
在医学科研的浩瀚星海中，一项重大突破犹如璀璨星辰，照亮了人类与癌症斗争的漫长旅程。2024年，全球医药界的目光聚焦于中国生物制药企业加科思-B（01167），其自主研发的Pan-KRAS抑制剂JAB-23E73新药临床实验申请（IND）在美国食品药品监督管理局（FDA）成功获批，犹如一记重锤敲响了抗癌战线的新篇章。这一里程碑式的事件，不仅标志着加科思-B在创新药物研发领域的重要突破，更预示着全球癌 ...
加科思-B(01167.HK)宣布其Pan-KRAS抑制剂AB-23E73新药临床实验申请(IND)在中国获批
格隆汇9月26日丨加科思-B(01167.HK)宣布，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请("IND")已经获得国家药品监督管理局(NMPA)药品审评中心(CDE)批准。此前，美国的IND申请也已经获得美国食品药品监督管理局("FDA")批准，将在中国和美国同步开展I/IIa期晚期实体瘤临床试验。KRAS广泛存在於多种肿瘤突变，约2 ...